Among them is Cayston®, an inhaled form of the
Developed by Gilead Sciences, Inc., Cayston is the first new inhaled antibiotic for CF developed in more than a decade. It offers a much-needed alternative for those who battle persistent P. aeruginosa lung infection and often develop
It is also the first drug to advance through the pipeline with Foundation support at every step of the way - from the initial discovery
“There's been rapid and broad acceptance of Cayston,” said George Z. Retsch-Bogart, M.D., a pediatric pulmonologist at the University of North Carolina at Chapel Hill and
Cayston is administered with a new device, the Altera® Nebulizer System, which allows patients to take the medicine in less than five minutes.
“It delivers a dose that is four to five times more efficient than our existing jet nebulizers,” said Dr. Retsch-Bogart, who also serves as medical director of the N.C. Children's Airway Center. “That's really important for people with CF, given how much we are already asking them to do in a day's time.”